Abstract
147P Population-adjusted indirect comparisons of repotrectinib and entrectinib in ROS1+ locally advanced or metastatic non-small cell lung cancer (NSCLC)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have